Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.2152W HIGH $13.43
Volume
103.86 K
Value Traded
39.73 M
Short % Float
11.11%
Days to Cover
3.9
-3.44%Week
+4.96%1 Month
-44.53%3 Month
-52.52%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
828.29 M
EPS (TTM)
-1.71
P/E Ratio
-
Ent. Value
2.68 B
Total Shares
136.26 M
Float Shares
86.36 M
Insiders
36.66%
Institutions
71.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AHCO Catalyst Timeline
Dated clinical, regulatory and corporate events for AdaptHealth Corp. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for AdaptHealth Corp. Common Stock
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How AHCO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
AdaptHealth Corp. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AHCO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WOLF DALE BDirector | Buy | 20,000 34,000 held | $5.86 | 08/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AHCO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| IRON TRIANGLE PARTNERS LP | 3 % (25 %) | 25.99 M | 2.61 M | 35.59% ( 684.87 K) |
AHCO Institutional Ownership Trends
AHCO Short Interest
Shares sold short, counted twice a month.
11.11%
Short % of Float
of tradable shares sold short
9.6M
Shares Sold Short
-0.4% vs prior count
3.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AHCO ranks across every disease it competes in
Competitive Position is a premium feature
See how AHCO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAHCO News
-AHCO
Oct 21, 2026▼ -0.4%today
AdaptHealth Corp. Announces Third Quarter 2026 Earnings Release Date and Conference Call
AdaptHealth Corp. will announce its third quarter 2026 earnings on November 3, 2026. The results will be released before market opening, followed by a teleconference at 8:30 a.m. ET. This event will allow management to discuss the financial outcomes and ongoing business activities.
Read more →-AHCO
Sep 11, 2026AdaptHealth To Participate in Upcoming Investor Conferences
AdaptHealth Corp. has announced its participation in upcoming investor conferences, including the 2026 Jefferies Healthcare Services and Technology Conference in Nashville. This involvement highlights the company's commitment to engaging with investors and showcasing its leadership in providing healthcare-at-home solutions. The event is scheduled for September 14, 2026.
Read more →-AHCO
Sep 8, 2026▼ -7.9%on this newsshared move
AdaptHealth Appoints Harriss Currie as Chief Financial Officer
AdaptHealth Corp. has appointed Harriss T. Currie as Chief Financial Officer, effective September 9, 2026. Currie will take over from Jason Clemens, who will support the transition process. This leadership change is expected to strengthen the company's financial management.
Read more →-AHCO
Aug 7, 2026▼ -8.3%on this news
AdaptHealth Corp. to Participate in Upcoming Investor Conferences
AdaptHealth Corp. has announced its participation in several upcoming investor conferences, including the Canaccord Genuity 46th Annual Growth Conference in Boston. This engagement highlights the company's commitment to connecting with investors and showcasing its leadership in healthcare-at-home solutions. The conference will feature a fireside chat, providing further insights into the company's operations.
Read more →-AHCO
Aug 4, 2026▼ -38%on this news
AdaptHealth Corp. Announces Second Quarter 2026 Results
AdaptHealth Corp. has reported its financial results for the second quarter of 2026, marking a successful period for the company. This quarter is notable as it is the first full quarter under a new exclusive capitated agreement with a major national integrated delivery network. The company remains a leader in providing home healthcare solutions.
Read more →-AHCO
Jul 20, 2026AdaptHealth Corp. Enters into Definitive Agreement to Divest Diabetes Health Business to Cardinal Health
AdaptHealth Corp. has announced the divestiture of its Diabetes Health business to Cardinal Health for $235 million in cash. This strategic move, finalized on July 19, 2026, allows AdaptHealth to concentrate on its primary offerings in home medical equipment and related services. The transaction reflects a significant shift in AdaptHealth's business strategy.
Read more →-AHCO
Jul 14, 2026AdaptHealth Corp. Announces Second Quarter 2026 Earnings Release Date and Conference Call
AdaptHealth Corp. has announced the release date for its second quarter 2026 earnings, set for August 4, 2026, before market opening. The company will hold a teleconference at 8:30 a.m. ET to discuss the financial results and business activities. This reflects the company's commitment to keeping stakeholders informed.
Read more →-AHCO
May 5, 2026▼ -9.9%on this news
AdaptHealth Corp. Announces First Quarter 2026 Results
AdaptHealth Corp. has announced its financial results for the first quarter of 2026. The article provides insights into the company's performance during this period. However, specific details regarding revenue, expenses, or other financial metrics are not included.
Read more →-AHCO
May 5, 2026▼ -9.9%on this news
ADAPTHEALTH CORP. ANNOUNCES FIRST QUARTER 2026 RESULTS
AdaptHealth Corp. announced its financial results for Q1 2026, reporting a 5.4% increase in net revenue to $819.8 million. The company achieved significant milestones, including the largest expansion in its industry and a successful refinancing of $1.1 billion. Despite these accomplishments, it reported a net loss of $16 million and elevated labor costs associated with its growth initiatives. The overall growth in revenue and user engagement reflects the company's strategic focus on enhancing its healthcare-at-home services.
Read more →-AHCO
Apr 14, 2026AdaptHealth Corp. Announces First Quarter 2026 Earnings Release Date and Conference Call
AdaptHealth Corp. has announced the date for its first quarter 2026 earnings release and the accompanying conference call. The announcement is part of the company's regular financial reporting schedule. Specific details regarding the earnings and call have not been disclosed in the article.
Read more →-AHCO
Apr 13, 2026AdaptHealth Corp. Announces Refinancing of Senior Secured Credit Facility Resulting in Extended Maturity, Reduced Cost of Debt, and Enhanced Financial Flexibility
AdaptHealth Corp. has announced a refinancing of its senior secured credit facility. This move extends the maturity of its debt, reduces the overall cost, and enhances the company's financial flexibility. These changes are expected to support the company's growth and operational strategies moving forward.
Read more →-AHCO
Feb 24, 2026▼ -13.9%on this news
ADAPTHEALTH CORP. ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS AND PROVIDES 2026 FINANCIAL GUIDANCE
AdaptHealth Corp. reported its fourth-quarter and full-year results for 2025, showing a slight decline in net revenue while achieving records in patient census for various health segments. The company made significant expansions, including the acquisition of a HME provider in Hawaii. Despite these accomplishments, AdaptHealth faced financial challenges, including a substantial net loss and a goodwill impairment charge. Looking ahead, the company has provided optimistic guidance for fiscal year 2026, emphasizing expectations for revenue growth and adjusted EBITDA improvements.
Read more →-AHCO
Nov 4, 2025▲ +17.4%on this news
ADAPTHEALTH CORP. ANNOUNCES THIRD QUARTER 2025 RESULTS
AdaptHealth Corp. announced its financial results for Q3 2025, reporting a net revenue increase of 1.8% to $820.3 million and organic growth of 5.1%. The company reduced its debt by $50 million in the quarter, contributing to a total debt reduction of $225 million year-to-date. Additionally, net income rose to $24.5 million, up from $22.9 million in the prior year period. CEO Suzanne Foster highlighted milestones achieved this quarter, including enhancements to operational efficiency and digital patient engagement.
Read more →-AHCO
Aug 5, 2025▲ +11%on this news
ADAPTHEALTH CORP. ANNOUNCES SECOND QUARTER 2025 RESULTS
AdaptHealth Corp. reported its financial results for the second quarter of 2025, showing a minor decrease in net revenue to $800.4 million and net income down to $14.7 million compared to the prior year. Despite these declines, the company highlighted an increase in cash flow from operations and announced the establishment of a new partnership with a national healthcare system. AdaptHealth updated its financial guidance for the fiscal year 2025, adjusting revenue forecasts upward. Challenges remain as the company struggles with lower adjusted EBITDA and free cash flow this quarter.
Read more →-AHCO
Aug 5, 2025▲ +11%on this news
AdaptHealth CORP. PARTNERS WITH A MAJOR NATIONAL HEALTHCARE SYSTEM TO BECOME THE EXCLUSIVE PROVIDER OF HOME MEDICAL EQUIPMENT
AdaptHealth Corp. has announced a definitive agreement to become the exclusive provider of home medical equipment and supplies for a major national healthcare system. This five-year partnership will serve over 10 million members and is expected to enhance patient-centered care at home. The agreement operates primarily under a capitation payment model and spans multiple patient categories, including Medicare and Medicaid. AdaptHealth's CEO highlighted the alignment of their services with the healthcare system's innovative approach to patient care.
Read more →-AHCO
May 6, 2025ADAPTHEALTH CORP. ANNOUNCES FIRST QUARTER 2025 RESULTS
AdaptHealth Corp. reported its financial results for Q1 2025, revealing a net revenue of $777.9 million, a decrease from the previous year's $792.5 million. The company also reported a net loss of $7.2 million, a significant increase compared to last year's loss of $2.1 million. Despite these setbacks, there was a notable increase in cash flow from operations. Nonetheless, the company is adjusting its financial guidance for the year following asset sales in its Wellness at Home segment.
Read more →-AHCO
Feb 25, 2025▲ +24.4%on this news
ADAPTHEALTH CORP. ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 RESULTS AND PROVIDES 2025 OUTLOOK
AdaptHealth Corp. reported its fourth quarter and full-year 2024 financial results, showcasing a net revenue increase to $3,261 million. The company achieved a significant turnaround, reporting a net income of $90.4 million, compared to a substantial loss the previous year. Despite a minor decline in fourth quarter revenue, AdaptHealth generated strong cash flow and provided a positive outlook for 2025, anticipating net revenue between $3.22 billion and $3.36 billion. Ongoing initiatives, including AI application and organic growth strategies, were highlighted by management as key drivers for future success.
Read more →-AHCO
Nov 5, 2024▼ -9.6%on this news
ADAPTHEALTH CORP. ANNOUNCES THIRD QUARTER 2024
AdaptHealth Corp. announced its financial results for the third quarter of 2024, reporting a slight increase in net revenue to $805.9 million and a return to profitability with a net income of $22.9 million. This marks a significant improvement compared to a net loss of $454.1 million in the same quarter last year. The company also highlighted increased adjusted EBITDA and cash flow from operations. The management has provided updated financial guidance for the fiscal year 2024, reflecting growing confidence in their market position and performance.
Read more →-AHCO
Oct 17, 2024ADAPTHEALTH CORP. FOR IMMEDIATE RELEASE AdaptHealth Appoints Diana Nole to Board of Directors
AdaptHealth Corp. announced the appointment of Diana Nole to its Board of Directors, effective October 16, 2024. Nole, with over 18 years of experience in healthcare technology, previously held high-level positions at Nuance Communications and Wolters Kluwer. Her leadership is expected to contribute to AdaptHealth's ongoing business transformation and growth initiatives. The company is optimistic about leveraging her expertise to enhance its healthcare-at-home solutions.
Read more →About AdaptHealth Corp. Common Stock
Headquarters555 EAST NORTH LANE, CONSHOHOCKEN, PA, 19428
BIOPHARMAWATCH ELITE PLUS
Trade the next AHCO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime